Taiwan-based Formosa Pharmaceuticals announced Feb. 23 that it had agreed to license to Arrotex Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain in Australia and New Zealand.

Financial details were not disclosed, but the companies said the deal included upfront, regulatory, and sales milestone payments, plus royalties.

Arrotex, based in Melbourne, is Australia’s largest and most diversified pharmaceutical company. Its product line includes topical medication for glaucoma.

Clobetasol propionate 0.05% (APP13007)—licensed in the US by Harrow and branded Byqlovi—was approved by the FDA in March 2024. The superpotent corticosteroid is new to ophthalmology. Formosa says its nanoparticle formulation offers a straightforward dosing regimen (twice daily for 14 days, with no tapering) and provides rapid and sustained relief of inflammation and pain.

Formosa has entered into a flurry of agreements licensing the drops globally, including with Apotex in Canada; Adalvo in the European and Brazilian markets; Tabuk Pharmaceuticals in the Middle East and North Africa; Cipla in India and 10 other countries; Laboratorios Saval in much of Latin America; Samil in South Korea; and Rxilient in some areas of Southeast Asia.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest